Amesite Inc. Reports Revenue Growth but Continues to Operate at a Loss

Amesite Inc. reported its financial results for the three and nine months ended March 31, 2026, revealing a significant increase in revenue compared to the same period last year. The company generated $83,332 in revenue for the three months ended March 31, 2026, up from $30,690 in the prior year, and $285,678 for the nine months, compared to $54,700 in the same period last year. Despite this growth, Amesite continues to operate at a loss, with a net loss of $678,061 for the three months and $2,052,875 for the nine months, although these figures represent a reduction from losses of $663,418 and $2,693,100, respectively, in the prior year.

The company’s financial position has seen notable changes, with total assets decreasing to $1,492,366 as of March 31, 2026, down from $3,097,099 at the end of the previous fiscal year. Cash and cash equivalents also fell significantly to $640,711 from $2,333,418. The decline in cash reserves is attributed to ongoing operational expenses and the need for continued investment in technology and content development. Operating expenses for the three months increased to $767,404, compared to $718,412 in the prior year, driven primarily by higher general and administrative costs.

Amesite has made strategic shifts in its business focus, particularly towards the healthcare sector with the launch of its NurseMagic™ app, which aims to streamline nursing documentation and enhance patient communication. This pivot is part of a broader strategy to target markets that demand immediate performance improvements and cost efficiencies. The company has also reported a reduction in its customer base risk by moving away from larger, upfront deals that have proven challenging to sustain. This strategic realignment is expected to foster growth in a more stable revenue environment.

Operationally, Amesite has seen a decrease in its employee headcount, which has contributed to lower personnel-related expenses. The company reported a total of 4,738,001 shares outstanding as of March 31, 2026, reflecting a modest increase from the previous period. The company’s focus on enhancing its technology platform has led to capitalized software costs of $206,700 for the nine months ended March 31, 2026, down from $292,200 in the prior year, indicating a more cautious approach to capital expenditures.

Looking ahead, Amesite acknowledges the challenges it faces in achieving profitability and maintaining sufficient cash flow. The company has raised approximately $2.6 million through recent financing activities, which it plans to use for working capital and general corporate purposes. However, management has expressed uncertainty regarding its ability to continue as a going concern, emphasizing the need for ongoing financing to support its operations. The company remains committed to its strategic initiatives and aims to leverage its AI-driven solutions to capture a larger share of the healthcare market while navigating the complexities of its financial landscape.